GenSight Biologics expands trial of Leber’s hereditary optic neuropathy treatment to include teenage patients

GenSight Biologics announced that regulatory agencies and ethics committees in the United States, France and the United Kingdom have approved a protocol amendment to include teenage patients aged 15 to 18 years in its two ongoing phase 3 clinical trials of GS010. According to a GenSight press release, the phase 3 RESCUE and REVERSE clinical trials are testing the use of GS010 in the treatment of Leber’s hereditary optic neuropathy.

Full Story →